ClinicalTrials.gg
Active, not recruitingNCT06448429Updated Sep 11, 2026

Testing an Integrated Care Model Trial

An interventional study of Usual care and Collaborative care model (CoCM) in Diabetes Mellitus, Type 1, sponsored by Emory University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Diabetes Mellitus, Type 1 by Emory University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Emory University.

Planned enrollment
4th of 13
80 · median 24
Started
2024
the only one that year
No phase
5 of 14
4 open now
Registered
10th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 1 by Emory University, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 5 with no phase, and was the 10th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

5 of the 14 studies in Diabetes Mellitus, Type 1 by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 1 by Emory University, or all of them as a file.
02

Study summary

This study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (T1D). The duration of the study is 18 months with 4 study survey points. Participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral health consultant during the first year (active intervention period).

Read the detailed description

Type 1 diabetes (T1D) is a lifelong condition that requires consistent monitoring and management, increasing people's risk for common mental disorders that worsen diabetes self-care. Both depression and diabetes can be managed with behavioral interventions, however, they are rarely provided alongside routine diabetes care for people with T1D. In this research study, the investigators aim to evaluate the implementation and effectiveness outcomes of a collaborative care model that uses a Behavioral Health Consultant (BHC) to support lifestyle management among adults with T1D receiving diabetes care at the Grady Diabetes Clinic.

A trained clinical research coordinator will screen interested patients seeking treatment at the Grady Diabetes Center and conduct outreach to individuals who have been identified as having T1D within the Grady Diabetes Center's patient population.

Participants in the intervention group will engage with a behavioral health consultant (BHC) not affiliated with Grady who will work with them to establish personalized health goals and identify ways to manage stress and promote healthy behaviors as means to support their mental and physical health and meet their set goals (i.e., behavioral activation). Each session will be conducted over the telephone or Zoom and last 30-60 minutes, with the number and frequency of meetings established through discussions between the patient and BHC (typically 2-3 sessions for one year). Checklist and summary case reporting templates will be used to track intervention fidelity. The BHC will also participate in ongoing Zoom calls with the multi-disciplinary T1D clinical team at the Grady Diabetes Center once a month to provide updates on patients' behavioral health plans. Transitioning patients from the active intervention will involve discussions with the care team to ensure continued patient support. In cases of active suicidal ideation, the study team will notify the patient's usual diabetes care provider and the individual will be referred to psychiatric services at Grady.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Behavioral Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with T1D (based on clinical record diagnosis).

Exclusion criteria

Exclusion Criteria:

  • Patients who do not speak English or have reliable telephone access will be excluded. ---
  • Individuals with the presence of severe psychiatric illness (PHQ-9≥20) or active suicidal ideation will also be excluded and referred to specialty care.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Collaborative care group

    Enrolled participants assigned to the intervention arm will be offered free consultation services with a behavioral health specialist, who is also a licensed clinical social worker. Participants randomized into the intervention group will consult with a behavioral health consultant (BHC) one or more times over the intervention period (based on the assessment of the BHC) via phone or Zoom based on the participant's preference. The BHC will participate in systematic caseload reviews to facilitate the medical management of depression if indicated.

    Other: Usual care · Other: Collaborative care model (CoCM)

  • Active comparator
    Usual Care

    Participants randomized to the usual care will continue their routine clinical care at the diabetes clinic at Grady.

    Other: Usual care

Interventions

  • OtherUsual care

    Participants will have the usual diabetes care at the Grady Diabetes Clinic.

    Also known as: Standard of Care (SOC)

  • OtherCollaborative care model (CoCM)

    Collaborative care will include: * Care with a behavioral health consultant (BHC) * Measurement-based mental health care * Systematic caseload reviews * Medical management of depression The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care.

    Also known as: Integrated Care Model

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving improvements in PHQ-9 score

    The proportion of patients achieving improvements in PHQ-9 score \[PHQ-9\<10\] or a ≥50% PHQ-9 score reduction.

    Time frame: Baseline, 12 months, and 18 months

  2. Proportion of patients achieving improvement in HbA1c at end of intervention

    Improvement in HbA1c will be considered as HbA1c\<7 or ≥0.5% HbA1c reduction

    Time frame: Baseline, 12 months, and 18 months

Secondary outcomes

  1. Generalized anxiety disorder scale score

    Researchers will use the Generalized anxiety disorder (GAD)-7, a 7-item scale with reporting scores from 0 to 3 on all the questions. It investigates how often the patient has been bothered by seven different symptoms of anxiety during the last two weeks with response options such as: " not at all," " several days '," more than half the days," and " nearly daily " scored as 0, 1, 2, and 3, respectively. The GAD-7 is scored by adding the scores for all 7 items, giving a total score from 0 to 21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate, and severe anxiety, respectively. Further evaluation is recommended when the score is 10 or greater.

    Time frame: Baseline, 12 months, and 18 months

  2. Systolic and diastolic blood pressure (BP) measurements

    Systolic and diastolic blood pressure (SBP and DBP) will be extracted from participants' medical records.

    Time frame: Baseline, 12 months, and 18 months

  3. Low-density lipoprotein (LDL) cholesterol

    LDL cholesterol data will be extracted from participants' medical records.

    Time frame: Baseline, 12 months, and 18 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Researchers will share deidentified individual participant data that underlie the results reported in published articles, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available beginning 3 months and ending 5 years following article publication.

Access criteria: Proposals should be directed to lmunoz@emory.edu. To access, the data requesters will sign a data access agreement. Data will be available for 5 years on Emory Dataverse.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 32 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 7, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06448429
Lead sponsor
Emory University
Collaborators
MQ Mental Health Research, Juvenile Diabetes Research Foundation
Responsible party
Leslie Johnson (Assistant Professor, Emory University) — Principal investigator
First posted
Jun 7, 2024
Start date
Jun 10, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Leslie Johnson, PhD, MPH
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion